Abstract Tyrosine phosphorylation is one of the key covalent modifications that occurs in multicellular organisms as a result of intercellular communication during embryogenesis and maintenance of adult tissues. The enzymes that carry out this modification are the protein tyrosine kinases (PTKs), which catalyze the transfer of the γ phosphate of ATP to tyrosine residues on protein substrates. Phosphorylation of tyrosine residues modulates enzymatic activity and creates binding sites for the recruitment of downstream signaling proteins. Two classes of PTKs are present in cells: the transmembrane receptor PTKs and the nonreceptor PTKs. Because PTKs are critical components of cellular signaling pathways, their catalytic activity is strictly regulated. Over the past several years, high-resolution structural studies of PTKs have provided a molecular basis for understanding the mechanisms by which receptor and nonreceptor PTKs are regulated. This review will highlight the important results that have emerged from these structural studies.
INTRODUCTION
One of the fundamental mechanisms by which cells in multicellular organisms communicate is the binding of polypeptide ligands to cell surface receptors that possess tyrosine kinase catalytic activity. Receptor tyrosine kinases (RTKs) are transmembrane glycoproteins that are activated by the binding of their cognate ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. RTKs activate numerous signaling pathways within cells, leading to cell proliferation, differentiation, migration, or metabolic changes (1) . The RTK family includes the receptors for insulin and for many growth factors, such as epidermal growth factor (EGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and nerve growth factor (NGF). In addition to the RTKs, there exists a large family of nonreceptor tyrosine kinases (NRTKs), which includes Src, the Janus kinases (Jaks), and Abl, among others. The NRTKs are integral components of the signaling cascades triggered by RTKs and by other cell surface receptors such as G protein-coupled receptors and receptors of the immune system. The specific reaction catalyzed by PTKs is the transfer of the γ phosphate of ATP to the hydroxyl group of a tyrosine in a protein substrate. The need for tight regulation of PTK catalytic activity is underscored by the numerous PTKs that have been identified as oncogenes (2, 3) .
The focus of this review is on the insights into molecular mechanisms of PTK regulation gained through high-resolution structural studies. Before reviewing the structural studies, a brief section on the roles of various PTKs in cellular signaling is presented, followed by a general discussion of some of the regulatory mechanisms to which PTKs are subject.
Protein Tyrosine Kinases in Cellular Signaling
Several examples are cited to illustrate the importance of PTKs in embryonic development, metabolism, and immune system function. The development of the vascular system relies on the concerted action of several subfamilies of RTKs and their cognate ligands (4) . The vascular system is formed in a two-step process. In the first step, referred to as vasculogenesis, endothelial cells differentiate to form a crude network of interconnected vessels. In the second step, termed angiogenesis, the vessels are remodeled and extended, and nonendothelial support cells are recruited to the maturing vasculature. Vasculogenesis requires the growth factor VEGF and one of the RTKs through which it acts, KDR. Angiogenesis requires another VEGF receptor, Flt1, as well as the angiogenic factor angiopoietin 1, which is a ligand for the RTK Tie2. More recently implicated in angiogenesis (in the demarcation of arteries and veins) is the ligand ephrinB2 and the RTK EphB4 (5) . Ephrins and the Eph receptors are better known for their roles in axon guidance (6) .
The effects of the hormone insulin are mediated by the insulin receptor, an RTK family member. Insulin binding to its receptor results in receptor activation and the recruitment of a family of downstream signaling molecules, the IRS proteins, to the activated receptor (7) . The IRS proteins are adaptor proteins, i.e. they have no identifiable catalytic function, which are phosphorylated on multiple tyrosine residues by the insulin receptor. Activation of phosphoinositide 3-kinase (PI-3K) through binding to phosphorylated IRS is a critical step in the translocation of glucose transporters to the cell membrane to facilitate glucose uptake (8, 9) .
The largest subfamily of NRTKs, with nine members, is the Src family. Src family members participate in a variety of signaling processes, including mitogenesis, T-and B-cell activation, and cytoskeleton restructuring. Multiple in vivo substrates have been described for Src and include, among others, the PDGF and EGF receptors; the NRTK focal adhesion kinase (Fak); p130Cas, an adapter protein involved in integrin-and growth factor-mediated signaling; and cortactin, an actin-binding protein important for the proper formation of cell matrix contact sites (10) . Src has also been implicated in several human carcinomas, including breast, lung, and colon cancer (10) .
NRTKs are critical components in the regulation of the immune system. The Jak family of NRTKs are noncovalently associated with the cytoplasmic domain of cytokine receptors, such as the interferon-γ receptor, and they are activated by ligand-induced receptor oligomerization. Activated Jaks then phosphorylate the cytokine receptors with which they are associated, providing binding sites for the Stat family of transcription factors. Phosphorylation of Stats by Jaks leads to Stat dimerization, translocation to the nucleus, and transcription of specific genes (11) .
Signaling by activated T and B cells of the immune system is dependent on multiple NRTKs (12) . The Src family member Lck is constitutively associated with the CD4 or CD8 receptor on T lymphocytes. Upon engagement of the T-cell receptor with antigen, Lck becomes autophosphorylated and phosphorylates the ζ chain of the T-cell receptor, providing binding sites for another NRTK, Zap70. Zap70 is recruited to the T-cell receptor, activated via phosphorylation by Lck, and then participates in downstream signaling events that mediate transcriptional activation of cytokine genes. Likewise, upon stimulation of the B-cell receptor, the Src family member Lyn is activated, which leads to the recruitment and phosphorylation of Syk, a Zap70-related NRTK. Another NRTK, Btk, also plays an important role in B-cell signaling. Mutations in the Btk gene are responsible for X-linked agammaglobulinemia (13, 14) , a disease characterized by the lack of mature B cells.
Overall Protein Architecture
RTKs consist of an extracellular portion that binds polypeptide ligands, a transmembrane helix, and a cytoplasmic portion that possesses tyrosine kinase catalytic activity (Figure 1 ). The vast majority of RTKs exist as a single polypeptide chain and are monomeric in the absence of ligand. Exceptions include Met and its family members, which comprise a short α chain disulfide-linked to a membrane-spanning β chain, and the insulin receptor and its family members, which consist of two extracellular α chains disulfide-linked to two membrane-spanning β chains. The α chains are also disulfide-linked to one another, forming an α 2 β 2 heterotetramer. Most polypeptide ligands for RTKs are soluble. Exceptions include the ephrins, the ligands for the Eph receptor family, which either span the cell membrane or are tethered to the membrane via a GPI (glycosyl-phosphatidylinositol) linkage (15, 16) .
The extracellular portion of RTKs typically contains a diverse array of discrete globular domains such as immunoglobulin (Ig)-like domains, fibronectin type IIIlike domains, cysteine-rich domains, and EGF-like domains. In contrast, the domain organization in the cytoplasmic portion of RTKs is simpler, consisting of a juxtamembrane region (just after the transmembrane helix), followed by the tyrosine kinase catalytic domain and a carboxy-terminal region. Some receptors, most notably members of the PDGF receptor family, contain a large insertion of ∼100 residues in the tyrosine kinase domain. The juxtamembrane and carboxy-terminal regions vary in length among RTKs. Along with the tyrosine kinase insert, these regions contain tyrosine residues that are autophosphorylated upon ligand binding.
NRTKs lack receptor-like features such as an extracellular ligand-binding domain and a transmembrane-spanning region, and most NRTKs are localized in the cytoplasm (17) . Some NRTKs are anchored to the cell membrane through aminoterminal modification, such as myristoylation or palmitoylation. In addition to a tyrosine kinase domain, NRTKs possess domains that mediate protein-protein, protein-lipid, and protein-DNA interactions ( Figure 2 ). The most commonly found protein-protein interaction domains in NRTKs are the Src homology 2 (SH2) and 3 (SH3) domains (18) . The SH2 domain is a compact domain of ∼100 residues that binds phosphotyrosine residues in a sequence-specific manner. The smaller SH3 domain (∼60 residues) binds proline-containing sequences capable of forming a polyproline type II helix.
Some NRTKs lack SH2 and SH3 domains but possess subfamily-specific domains used for protein-protein interactions. For example, members of the Jak family contain specific domains that target them to the cytoplasmic portion of cytokine receptors. The NRTK Fak possesses two domains that mediate protein-protein interactions: an integrin-binding domain and a focal adhesion-binding domain. The NRTK Abl contains a nuclear localization signal and is found in both the nucleus and the cytoplasm. In addition to SH2 and SH3 domains, Abl possesses an F actin-binding domain and a DNA-binding domain.
Another modular domain, present in the Btk/Tec subfamily of NRTKs and in many other signaling proteins, is the pleckstrin homology (PH) domain. PH 
REGULATION OF RECEPTOR TYROSINE KINASES Tyrosine Autophosphorylation
Activation of RTKs typically requires two processes: enhancement of intrinsic catalytic activity and creation of binding sites to recruit downstream signaling proteins. For the majority of RTKs, both of these processes are accomplished by autophosphorylation on tyrosine residues, a consequence of ligand-mediated oligomerization. In general, autophosphorylation of tyrosines in the activation loop within the kinase domain results in stimulation of kinase activity, and autophosphorylation of tyrosines in the juxtamembrane, kinase insert, and carboxy-terminal regions generates docking sites for modular domains that recognize phosphotyrosine in specific sequence contexts. The two well-established phosphotyrosinebinding modules present within signaling proteins are the SH2 domain and the phosphotyrosine-binding (PTB) domain (18) . Two examples serve to illustrate the recruitment roles of phosphotyrosines on activated RTKs. The juxtamembrane region of TrkA, the receptor for NGF, contains a tyrosine in an NPXY motif that, upon autophosphorylation, becomes an interaction site for the PTB domain of Shc (20, 21) . Engagement of Shc via this autophosphorylation site leads to Shc phosphorylation by TrkA, recruitment of Grb2 and Sos to phosphorylated Shc, and Ras activation. Similarly, within the carboxy-terminal tail of FGF receptor 1 resides a tyrosine autophosphorylation site that serves as a high-affinity binding site for the SH2 domain of phospholipase Cγ (PLCγ ). The recruitment of PLCγ to FGF receptor 1 via this autophosphorylation site leads to phosphorylation and activation of PLCγ by the receptor (22, 23) .
All RTKs thus far identified contain between one and three tyrosines in the kinase activation loop, which comprises subdomains VII and VIII of the protein kinase catalytic core (24) . Phosphorylation of these tyrosines has been shown to be critical for stimulation of catalytic activity and biological function for a number of RTKs, including the insulin receptor (25) , FGF receptor (26) , VEGF receptor (27) , PDGF receptor (28), Met (hepatocyte growth factor receptor) (29) , and TrkA (30) . The major exception to catalytic enhancement via activation loop autophosphorylation is the EGF receptor. Although a tyrosine in the activation loop is conserved in this RTK subfamily, substitution with phenylalanine has no demonstrable effect on the signaling properties of the receptor (31) .
In principle, receptor autophosphorylation could occur in cis (within a receptor) or in trans (between receptors). In the first case, ligand-induced dimerization would cause a conformational change in the receptor that would facilitate cis-autophosphorylation. In the second case, no conformational change need occur upon dimerization; a simple proximity effect would provide sufficient opportunity for trans-autophosphorylation to occur. Based on structural studies of the insulin receptor kinase domain (32, 33) , steric considerations indicate that activation loop tyrosines in PTKs can only be phosphorylated in trans. Other autophosphorylation sites (e.g. in the juxtamembrane region or carboxy-terminal tail) could potentially be autophosphorylated in cis.
Dimerization
As discussed above, tyrosine autophosphorylation is the essential modification that occurs during RTK activation. Ligand-induced oligomerization of RTKs is the mechanism by which tyrosine autophosphorylation is triggered (34, 35) . Ligand binding to the extracellular portion of RTKs mediates the noncovalent oligomerization of monomeric receptors or induces a structural rearrangement in heterotetrameric receptors (e.g. the insulin receptor), facilitating tyrosine autophosphorylation in the cytoplasmic domains.
Whether receptor dimerization is sufficient for signal transmission or whether higher-order oligomerization is required has not been fully resolved; it likely depends on the particular ligand-RTK system. For receptors that bind dimeric ligands, such as the PDGF receptor, a receptor dimer is likely to be a competent signaling unit. However, not all dimeric configurations of a receptor are capable of signaling. The introduction of cross-linking cysteine residues into the transmembrane helix of ErbB2, an EGF receptor family member, indicates that ErbB2 activation is dependent on the relative orientation of the two receptors in the dimer (36) . For Eph receptors, biochemical studies show that although a dimeric ephrin is sufficient for receptor autophosphorylation, a tetrameric ephrin is necessary to elicit the full range of biological responses in cells (37) . In most cases, RTK dimerization is probably sufficient for transducing the biological signal.
Ligand binding stabilizes a dimeric configuration of the extracellular domains of RTKs, but the spatial relationship between the tyrosine kinase-containing cytoplasmic domains within the dimer is not well understood. The cytoplasmic domains may associate only transiently, acting as enzyme and substrate for the other, or they may interact stably to form a symmetric (or asymmetric) dimer before and/or after autophosphorylation. For those RTKs whose kinase activity is stimulated via activation loop phosphorylation, the transient association model appears to be consistent with the available biochemical data. In this model, all sites could conceivably be autophosphorylated within the dimer (i.e. higher-order receptor interactions would not be required).
If the two cytoplasmic domains in the ligand-mediated dimer form a stable complex before autophosphorylation, steric constraints would preclude transautophosphorylation of a subset of sites (those nearest the kinase domains), in which case higher-order receptor association would be necessary to complete autophosphorylation. For the EGF receptor, which does not undergo activation loop autophosphorylation, biochemical evidence suggests that a cytoplasmic domain dimer is required for catalytic enhancement (38, 39) ; autophosphorylated but monomeric EGF receptors are not activated. Interestingly, all of the identified autophosphorylation sites in the EGF receptor are in the long carboxy-terminal tail of the receptor. It is conceivable (from steric considerations) that all of these sites could be autophosphorylated by the cytoplasmic domain dimer, although evidence exists for autophosphorylation occurring between pairs of EGF receptor dimers (40) . A further level of positive regulation may come from Src phosphorylation of Tyr-845 in the activation loop (41, 42) .
Additional Mechanisms
In the simple RTK activation model, ligand-mediated dimerization of the extracellular domains promotes transient association of the cytoplasmic domains to facilitate trans-autophosphorylation. In this model, tyrosine to phenylalanine substitutions of nonactivation loop autophosphorylation sites should not adversely affect autophosphorylation of the remaining sites. For some RTKs (e.g. the PDGF receptor), the activation process appears to be more complicated. Substitution of two tyrosines with phenylalanine in the juxtamembrane region of the PDGFβ receptor drastically reduces autophosphorylation of the numerous other sites in the receptor, which are readily autophosphorylated in the wild-type receptor (43, 44) . One possible explanation for this phenomenon is that autophosphorylation of the juxtamembrane sites relieves an inhibitory restraint, similar to the effect of activation loop autophosphorylation. Interestingly, autophosphorylation of the activation loop tyrosine in the PDGFβ receptor has been shown to be critical for phosphorylation of exogenous substrates but not for autophosphorylation (44) .
Downregulation of RTKs occurs via several processes, including receptormediated endocytosis (45), ubiquitin-directed proteolysis (46) , and the action of protein tyrosine phosphatases (PTPs) (47) . Although it has proven somewhat difficult to determine whether specific PTPs are responsible for dephosphorylating specific RTKs in vivo, examples are beginning to emerge. In Caenorhabditis elegans, loss-of-function mutations in the CLR-1 PTP give a phenotype that mimics constitutive activation of the FGF receptor ortholog, EGL-15, implicating this PTP in the regulation of FGF receptor-mediated signaling in nematodes (48) . Disruption of the gene encoding PTP1B in mice results in a phenotype that indicates that at least one of the functions of PTP1B is to dephosphorylate the insulin receptor (49) .
REGULATION OF NONRECEPTOR TYROSINE KINASES
The most common theme in NRTK regulation, as in RTK regulation, is tyrosine phosphorylation. With few exceptions, phosphorylation of tyrosines in the activation loop of NRTKs leads to an increase in enzymatic activity. Activation loop phosphorylation occurs via trans-autophosphorylation or phosphorylation by a different NRTK. Phosphorylation of tyrosines outside of the activation loop can negatively regulate kinase activity. PTPs restore NRTKs to their basal state of activity or, in some cases, positively regulate NRTK activity (47) .
Src and Abl
Regulation of Src catalytic activity has been studied extensively (50) . Src and its family members contain a myristoylated amino terminus, a stretch of positivelycharged residues that interact with phospholipid head groups, a short region with low sequence homology, an SH3 domain, an SH2 domain, a tyrosine kinase domain, and a short carboxy-terminal tail (Figure 2 ). Src possesses two important regulatory tyrosine phosphorylation sites. Phosphorylation of Tyr-527 in the carboxy-terminal tail of Src by the NRTK Csk represses kinase activity (51) . The importance of this phosphorylation site is underscored by v-Src, an oncogenic variant of Src that is a product of the Rous sarcoma virus. Owing to a carboxy-terminal truncation, v-Src lacks the negative regulatory site Tyr-527 and is constitutively active, leading to uncontrolled growth of infected cells (52) . Moreover, substitution of this tyrosine with phenylalanine in c-Src results in activation (53) . A second regulatory phosphorylation site in Src is Tyr-416, an autophosphorylation site in the activation loop. Maximal stimulation of kinase activity occurs when Tyr-416 is phosphorylated, and a Tyr-416→Phe mutation can suppress the transforming ability of the activating Tyr-527→Phe mutation (53) .
Both the SH2 and SH3 domains have been implicated in the negative regulation of Src activity (50) ; mutations in the SH2 and SH3 domains that disrupt binding of phosphotyrosine and proline-rich sequences, respectively, activate Src. The mechanisms by which the SH2 and SH3 domains repress Src kinase activity have been elucidated through X-ray crystallographic studies and are discussed below.
Although the NRTK Abl contains SH3, SH2, and kinase domains in the same linear order as in Src (Figure 2 ), regulation of Abl differs from that of Src. Abl lacks the negative regulatory phosphorylation site that is present in the carboxy terminus of Src. In contrast to Src, the carboxy terminus of Abl does not have a functional role in the control of kinase activity, and mutations in the SH2 domain of Abl that abrogate phosphotyrosine binding do not activate Abl in vivo (54) . The SH3 domain of Abl, however, does play a role in the repression of kinase activity; mutations in the SH3 domain result in activation of Abl and cellular transformation (55) . Significantly, the mutations in the SH3 domain have no effect on tyrosine kinase activity in vitro, which suggests that the SH3 domain binds to a cellular inhibitor in vivo. A leading candidate for such an inhibitor is Pag/MSP23, a member of the peroxiredoxin family of antioxidant enzymes. Pag/MSP23 is capable of complexing with the SH3 domain of Abl and inhibiting Abl kinase activity when overexpressed (56) .
Zap70/Syk and Jaks
The SH2 domains of Syk have been implicated in the regulation of Syk kinase activity. Engagement of the two SH2 domains of Syk with the tyrosine-phosphorylated ITAM (immunoreceptor tyrosine-based activation motif) sequences in the ζ chain of the T-cell receptor is thought to relieve an inhibitory restraint on the kinase domain, leading to stimulation of catalytic activity (57) . Phosphorylation of Tyr-493 in the Zap70 activation loop by Src family member Lck has been shown to increase Zap70 catalytic activity (58) . Curiously, mutation of the adjacent Tyr-492 to phenylalanine results in Zap70 hyperactivity, which suggests that phosphorylation of Tyr-492 is inhibitory (59) . It remains to be demonstrated, however, that this hyperactivity is caused by a negative effect of Tyr-492 phosphorylation rather than a positive (aberrant) effect of phenylalanine vs tyrosine.
In addition to a fully functional tyrosine kinase domain, Jak family members possess a pseudo-kinase domain in which substitution of several key catalytic residues renders the domain inactive (60) . Although enzymatically nonfunctional, the pseudo-kinase domain may play a role in the regulation of Jak activity. A mutant of the Jak family member Tyk2, in which the pseudo-kinase domain is deleted, lacks catalytic activity in vitro and is not capable of interferon-mediated signal transduction (61) . In contrast, a Jak2 mutant lacking the pseudo-kinase domain was able to mediate growth hormone signaling (62) . Thus, the role of the pseudo-kinase domain in Jak regulation is not fully understood.
Like Zap70/Syk, Jaks possess twin tyrosine phosphorylation sites within the activation loop. Autophosphorylation of the first of these tyrosines is important for stimulation of tyrosine kinase activity and biological function (63, 64) . The role of the second tyrosine is less clear. In Jak2, substitution of the second tyrosine with phenylalanine had no obvious effect (63) , whereas the same substitution in Jak3 resulted in an increase in kinase activity (64) , akin to the effect of the Tyr-492→Phe mutation in Zap70.
Jaks are also regulated by SOCS (suppressor of cytokine signaling) proteins. These proteins contain a pseudo-substrate sequence thought to interfere with Jak substrate binding and phosphoryl transfer (65) . In addition to a pseudo-substrate sequence, SOCS proteins possess an SH2 domain that binds to a phosphotyrosine in the Jak activation loop (66) , which may facilitate interaction between the pseudosubstrate sequence and the kinase domain. Binding of the SH2 domain to the activation loop could also block substrate access directly or alter the conformation of the activation loop to repress catalytic activity. structure of VEGF in complex with Ig-like domain 2 (D2) of Flt1 (67) provides a picture of the simplest dimerization scenario: a dimeric ligand engaging two receptors. The structure shows a nearly twofold symmetric arrangement of VEGF and two molecules of D2 (Figure 3) . The interface between VEGF and D2 consists mainly of hydrophobic residues, and the two equivalent receptor-binding sites on the VEGF dimer comprise residues from both of the VEGF protomers, i.e. the receptors bind at the junctions of the VEGF protomers. Domain deletion studies indicate that VEGF binds to D2-D3 with 20-fold higher affinity than to D2 alone (67) . This result, along with the observed positioning of VEGF near the carboxyterminal end of D2, suggests that VEGF also makes contact with D3 over a limited area.
STRUCTURAL STUDIES OF RECEPTOR TYROSINE KINASES

Ligand-Binding Domains
Another example of how a dimeric ligand engages two RTK molecules is illustrated by the crystal structure of NGF bound to the ligand-binding domain of its receptor TrkA (68) . The extracellular portion of TrkA comprises two cysteine-rich domains separated by a leucine-rich domain, followed by two Ig-like domains (Figure 1) . The Ig-like domain proximal to the cell surface, D5, is sufficient for binding NGF. Analysis of the ligand-receptor interactions observed in the structure, together with sequence comparisons with related neurotrophic factors (BDNF and NT3) and RTKs (TrkB and TrkC), indicates that there is one NGF-D5 interaction site that is common in all neurotrophin-Trk binding and a second interaction site that determines specificity (68) . As in the VEGF-D2 interaction, the two D5 molecules bind at the interface between the two NGF protomers.
The crystal structure of basic FGF (FGF2) bound to the ligand-binding domain of FGF receptor 1 (69) provides another distinct example of how ligand binding induces RTK dimerization. The extracellular portion of FGF receptors contains three Ig-like domains, the last two of which (D2-D3) are sufficient for FGF binding. FGFs bind to their receptors to form a 1:1 ligand:receptor complex and require heparin sulfate proteoglycans for receptor dimerization (70) . Although no heparin analog was included in the crystallization solution, the asymmetric unit comprises two 1:1 FGF2:D2-D3 complexes related by a pseudo-dyad axis (Figure 4 ). FGF2 engages residues in D2, D3, and the linker that connects the two domains.
Compared with the extensive interactions between FGF2 and D2-D3 in the 1:1 complex, the dimer is stabilized by relatively few contacts, which is consistent with the inability of FGF under normal physiological conditions to dimerize its receptor in the absence of heparin. Stabilization of the dimer comes from contacts between FGF2 and the other D2-D3 molecule in the dimer and from receptorreceptor contacts at the base of D2. In contrast to disulfide-linked VEGF and NGF, the two FGF2 molecules are located distally in the dimer and do not contact each other. Calculation of the electrostatic potential at the surface of the dimer reveals an extensive area of positive potential along the inward faces of D2, extending onto the top surface of the adjoining FGF2 molecules. Many of the lysine and arginine residues that contribute to the positive potential in both the receptor and ligand have been implicated in heparin binding. Manual docking of a heparin dodecasaccharide into this region (Figure 4) suggests that a heparin molecule of sufficient length (octasaccharide or longer) could interact with the heparin-binding residues of the receptors and also the adjoining ligands.
Three other structures of RTK ligand-binding domains have been reported, although they do not include bound ligand. A crystal structure of the first three domains of the insulin-like growth factor 1 (IGF1) receptor (71) provides clues to the mode of binding of IGF1 and insulin to their respective, related receptors. Domains 1 and 3 of the IGF1 and insulin receptors are so-called L domains (L1 and L2), and domain 2 is rich in cysteines (Figure 1 ). The extracellular portion of members of the EGF receptor family also contains these same three domains followed by another cysteine-rich domain. The L domains feature a β-helix-type fold, with α helices flanking the amino-and carboxy-terminal ends ( Figure 5 ). The cysteine-rich domain comprises an array of disulfide-linked modules resembling those in tumor necrosis factor receptor (72) and laminin (73) .
An important structural feature is the interaction between L1 and the adjacent cysteine-rich domain. A tryptophan residue from the cysteine-rich domain is embedded in the hydrophobic core of L1. This interaction presumably fixes the orientation of L1 with respect to the cysteine-rich domain. Interestingly, this tryptophan is conserved in both of the cysteine-rich domains of the EGF receptor. In contrast, no contacts are observed between the cysteine-rich domain and the following L2, which suggests an inherent flexibility between these two domains that may be important for ligand binding.
A large cleft is formed by the L domains and the cysteine-rich domain ( Figure 5 ), which is the putative ligand-binding site. A β sheet on the bottom of L1 and a loop from the cysteine-rich domain line the cleft. Residues important for IGF1 and insulin binding have been mapped to these regions (71) . The cleft as observed in the crystal structure is too large to bind IGF1 productively, but a rotation of ∼25
• of L2 toward L1 would be sufficient to form a cleft of the appropriate size for IGF1.
A low-resolution, three-dimensional reconstruction of the insulin receptor with bound insulin has been determined by electron microscopy, which provides a model for the spatial organization of the various domains in the intact receptor (74) . The electron density envelope, at a nominal resolution of 20Å, was fit with the structures of individual domains determined at higher resolution by X-ray crystallography. The model indicates that one insulin molecule engages L1 and the cysteine-rich domain from one receptor α chain and L2 from the other α chain, consistent with the observed negative cooperativity of insulin binding and the low affinity of insulin for the monomeric form of the receptor (αβ). The model also indicates that in the insulin-bound state the tyrosine kinase domains are poised for trans-autophosphorylation.
The extracellular portion of Eph receptors contains two fibronectin type III repeats, a cysteine-rich region, and an amino-terminal domain that is sufficient for binding ephrins. The crystal structure of the unliganded amino-terminal domain of EphB2 shows that this domain adopts a jellyroll β-sandwich fold consisting of two five-stranded β sheets (75) . The two classes of Eph receptors, A and B, contain either 13 or 17 residues, respectively, in the loop connecting β-strands H and I, which suggests that this loop may be important in conferring ligand specificity. Mutagenesis studies support this hypothesis (75) .
Cytoplasmic Domains
Crystal structures of the tyrosine kinase domains from several RTKs have been reported. These followed the structure determinations of several related protein serine/threonine kinases (76), the first of which was cyclic AMP-dependent protein kinase (PKA) (77) . The overall architecture of the tyrosine kinase domain is similar to that of the serine/threonine kinases: an amino-terminal lobe comprising a five-stranded β sheet and one α helix, and a larger carboxy-terminal lobe that is mainly α-helical ( Figure 6 ). ATP binds in the cleft between the two lobes, and the tyrosine-containing peptide substrate binds to the carboxy-terminal lobe. Several residues are highly conserved in all protein kinases, including several glycines in the nucleotide-binding loop, a lysine in β-strand 3, a glutamic acid in α-helix C, an aspartic acid and asparagine in the catalytic loop, and a DFG motif in the beginning of the activation loop (76; Figure 6 ).
As discussed previously, autophosphorylation of tyrosines in the activation loop typically leads to stimulation of catalytic activity. Crystal structures of the unphosphorylated forms of the insulin receptor kinase domain (IRK) (32) and the FGF receptor kinase domain (FGFRK) (78) provide a molecular basis for understanding how catalytic activity is repressed before receptor activation. The activation loop of the insulin receptor contains three tyrosine autophosphorylation sites. In the crystal structure of unphosphorylated IRK, one of the tyrosines (Tyr-1162) is bound in the active site, hydrogen-bonded to a conserved aspartic acid and arginine in the catalytic loop (Figure 7) .
Although Tyr-1162 is seemingly in position to be autophosphorylated in cis, the conserved aspartic acid of the DFG motif (Asp-1150) in the beginning of the activation loop, which is involved in Mg-ATP binding (33, 76) , is not properly positioned for catalysis. It appears that the activation loop is too short to position simultaneously Asp-1150 for Mg-ATP binding and Tyr-1162 in the active site. Biochemical studies support a trans-autophosphorylation mechanism for Tyr-1162 (and Tyr-1158/1163) (79) . Substitution of Tyr-1162 with phenylalanine results in an increase in basal-level (no insulin) catalytic activity in the full-length receptor (25, 80) , consistent with an autoinhibitory role for Tyr-1162. Thus, the structural and biochemical data indicate that before autophosphorylation, Tyr-1162 competes with protein substrates (neighboring β chain and exogenous substrates) for the active site.
The FGFRK activation loop contains two tyrosine autophosphorylation sites, Tyr-653/654, corresponding to Tyr-1162/1163 in IRK. Despite >50% sequence identity in the FGFRK and IRK activation loops, the conformation of the unphosphorylated FGFRK activation loop as seen in the crystal structure is significantly different from that in IRK (78) . In the FGFRK structure, neither of the activation loop tyrosines are bound in the active site. Rather, the tyrosine kinase-invariant proline at the end of the activation loop and nearby residues are positioned to interfere with the binding of a substrate tyrosine. Furthermore, in contrast to IRK, the ATP-binding site in the FGFRK structure is not obstructed by the beginning of the activation loop.
The temperature factors (B-factors) derived during crystallographic refinement indicate that portions of the unphosphorylated IRK and FGFRK activation loops are quite mobile, suggesting that an equilibrium between multiple conformations exists in solution. A subset of these (e.g. those observed in the IRK and FGFRK crystal structures) will hinder substrate (protein and/or ATP) binding. For a given RTK, the conformational equilibrium for the unphosphorylated activation loop may have been "tuned" through amino acid variation to provide adequate autoinhibition to deter substrate phosphorylation prior to receptor activation, yet allow trans-autophosphorylation between receptors that have been dimerized via ligand binding. Point mutations in the activation loop of several RTKs that result in constitutive activation may alter this equilibrium (81) .
Crystal structures of the phosphorylated kinase domains of the insulin receptor (33) and Lck (82) , as well as structures of several phosphorylated protein serine/threonine kinases (77, 83, 84) , reveal the role of activation loop phosphorylation in the stimulation of catalytic activity. Autophosphorylation in the IRK activation loop brings about a dramatic repositioning of the loop (Figure 7 ). The conformation of the tris-phosphorylated IRK activation loop is stabilized in part by interactions involving the phosphotyrosines, particularly phosphorylated Tyr-1163 (pTyr-1163), which is hydrogen-bonded to a conserved arginine in the beginning of the activation loop (Arg-1155) and to a backbone amide nitrogen in the latter half of the loop. The activation loop of mono-phosphorylated Lck adopts a similar conformation, with pTyr-394 in the same spatial position as pTyr-1163 in IRK. In addition to phosphotyrosine interactions, the activation loops of IRK and Lck are stabilized by short β-strand interactions with other segments of the carboxy-terminal lobe.
The crystal structure of the tyrosine kinase domain of the VEGF receptor KDR has also been reported (85) . The VEGF receptors (KDR and Flt1), like the PDGF receptors, possess a large kinase insert between helices D and E in the carboxyterminal lobe. After failing to obtain crystals of KDR with an intact kinase insert, McTigue et al (85) were successful in crystallizing a protein in which 50 residues of the insert were deleted. KDR possesses two tyrosine autophosphorylation sites in its activation loop, Tyr-1054/1059, which correspond in sequence to Tyr-1158/1163 in the insulin receptor. The crystallized protein was phosphorylated on Tyr-1059. As with the insulin and FGF receptors, phosphorylation of the KDR activation loop has a stimulatory effect on kinase activity. As expected from the high degree of sequence similarity between the kinase domains of KDR and FGF receptor 1 (∼55% identity), the two structures are quite similar overall.
An unexpected feature of the KDR kinase structure is the configuration of the activation loop. Although phosphorylated, the activation loop is disordered in the region that includes pTyr-1059. This is in contrast to the structures of mono-phosphorylated Lck and tris-phosphorylated IRK, in which pTyr-394 and pTyr-1163, respectively, are well ordered and participate in specific interactions. The end of the KDR activation loop in the vicinity of conserved Pro-1168, which is ordered, adopts the same inhibitory conformation as that seen in the structure of unphosphorylated FGFRK. This suggests that crystallization conditions (e.g. high concentrations of salt or polyethylene glycol) or crystal packing forces may, in some instances, influence the conformational equilibrium of the activation loop.
The crystal structure of tris-phosphorylated IRK in complex with an ATP analog and a peptide substrate reveals the mode of substrate binding to tyrosine kinases (33) . The cocrystallized 18-residue peptide contains a YMXM motif, which is a favorable substrate sequence for the insulin receptor (86) . Only 6 of the 18 residues are ordered in the structure, and the residues of the YMXM motif bind as an antiparallel β strand to the end of the activation loop. The backbone-backbone interactions between the peptide and the activation loop ensure that only a tyrosine side chain can reach the active site; a serine or threonine side chain is too short. The methionine side chains fit into two shallow hydrophobic pockets on the surface of the carboxy-terminal lobe of the kinase. PTKs exhibit a modest degree of substrate sequence selectivity in the vicinity of the tyrosine (87) . The variability across the PTK family in the residues comprising the methionine-binding pockets presumably accounts for this selectivity, at least in part.
Stimulation of tyrosine kinase activity after activation loop autophosphorylation appears to result from two related effects: (a) removal of steric hindrances to substrate binding (Mg-ATP and peptide substrate) and (b) proper positioning of residues involved in substrate binding and catalysis. The beginning and end of the activation loop are the two important regions of the loop. The invariant aspartic acid of the DGF motif (involved in Mg-ATP binding) is found at the beginning of the activation loop, and the peptide substrate binds to the end of the loop. Additional, nonsteric effects on catalytic rate enhancement from autophosphorylation have been reported (88) , the nature of which remain to be elucidated.
The precise phosphoryl transfer mechanism used by PTKs, whether associative or dissociative (89) , is not fully understood. Related to this question is the role of the conserved aspartic acid in the catalytic loop (Asp-1132 in IRK), i.e. whether the aspartic acid acts as a catalytic base to abstract the proton from the tyrosine hydroxyl group or simply positions the hydroxyl group. Biochemical studies on the NRTK Csk indicate that the substrate tyrosine must be neutral for phosphoryl transfer to occur, an observation that is consistent with a dissociative mechanism (90, 91) .
Besides the tyrosine kinase domain, perhaps the only other bona fide globular domain in the cytoplasmic portion of RTKs is the sterile alpha motif (SAM) domain, which is present in the carboxy-terminal region of Eph receptors as well as in a wide variety of signaling and scaffolding proteins. SAM domains function as homo-and hetero-oligomerization modules. The crystal structures of the SAM domains from EphA4 (92) and EphB2 (93) both reveal a globular domain consisting of five α helices, but the interactions between SAM domains differ in the two structures. In the structure of the EphA4 SAM domain, there exists a crystallographic dimer whose interface comprises residues from the extended amino-terminal segment and the latter part of the carboxy-terminal α helix (92) . In contrast, in the EphB2 SAM domain structure, the asymmetric unit contains eight SAM domains, each of which interacts with its neighbors via two contact regions (distinct from the contact region in the EphA4 dimer), resulting in a continuous oligomeric structure (93) . Thus, clarification of the precise mode of oligomeric interaction between SAM domains will require additional biochemical studies.
STRUCTURAL STUDIES OF NONRECEPTOR TYROSINE KINASES
Src Family Tyrosine Kinases
The crystal structures of Src and Hck (another Src family member) provide a molecular framework for understanding the mechanism of regulation of this class of NRTKs (94) (95) (96) . As outlined above, phosphorylation of Tyr-416 in the activation loop positively regulates catalytic activity, whereas phosphorylation of Tyr-527 in the carboxy-terminal region negatively regulates activity. The crystallized proteins were phosphorylated at Tyr-527 and thus represent the downregulated, repressed forms.
In the crystal structures, pTyr-527 is engaged in an intramolecular interaction with the SH2 domain (Figure 8 ), as had been anticipated. Unexpected was the intramolecular interaction between the SH3 domain and the segment linking the SH2 domain with the kinase domain (SH2-kinase linker), which forms a short polyproline type II helix. The SH2-kinase linker in Hck contains a PXXP motif, the minimum consensus sequence for SH3 binding, but the linker in Src contains only one proline. Furthermore, high-affinity binding of SH3 domains to proline-rich sequences generally requires an arginine or lysine on either side of the PXXP motif (97) , which is absent in the linker. However, the proximity of the SH3 domain to the SH2-kinase linker (on the same polypeptide chain), together with stabilizing effects from the engagement of the SH2 domain with pTyr-527, favors the SH3 interaction with the SH2-kinase linker.
The crystal structures show that the mechanism by which Src kinase activity is repressed is not by occlusion of the active site by the SH2 or SH3 domains, as might have been expected. In fact, these two domains are situated on the back side of the kinase domain, opposite the catalytic cleft (Figure 8) . Instead, intramolecular interactions stabilize the misalignment of residues important for catalytic activity and also restrict the relative motion of the two kinase lobes to hinder productive ATP binding.
Structures of protein kinases exhibit considerable diversity in the positioning of the amino-terminal kinase lobe with respect to the carboxy-terminal lobe (95) . In the crystal structure of PKA in complex with a peptide inhibitor and ATP (ternary complex), the two lobes of the kinase domain are in close apposition, with ATP bound in between (98, 99) . This configuration represents an active kinase state. In contrast, the two lobes in the unphosphorylated, low-activity form of the insulin receptor kinase are comparatively far apart (32) .
In the crystal structures of downregulated Src/Hck, the two kinase lobes are also in a closed configuration. However, a major structural difference between Src/Hck and PKA is the positioning of α-helix C in the amino-terminal lobe. Within helix C is a glutamic acid (Glu-91 in PKA, Glu-310 in Src) that is conserved in all protein kinases. In the active form of PKA, the side chain of Glu-91 is salt-bridged to another protein kinase-invariant residue, Lys-72 (Lys-295 in Src), located in β-strand 3 of the amino-terminal β sheet. This lysine coordinates the α and β phosphate groups of ATP in the ternary PKA complex, and its position is affected by its interaction with Glu-91. The salt bridge between the lysine and glutamic acid is also present in the crystal structure of the phosphorylated (active) kinase domain of Lck (100). In the structures of downregulated Src/Hck, however, helix C is not packed against the β sheet in the same manner as in Lck, and Glu-310 is displaced >12Å from Lys-295, pointing away from the ATP-binding site ( Figure 9 ).
The position of helix C (and hence Glu-310) in Src/Hck is influenced by residues in the SH2-kinase linker. In particular, Trp-260 of the linker inserts into a hydrophobic pocket at the carboxy-terminal end of the helix, stabilizing the nonproductive position of the helix. In the Lck structure, the side chain of Trp-260 adopts a conformation that favors the catalytically productive position of helix C. Mutation of Trp-260 to alanine in Src/Hck results in constitutive activation (101, 102) . Another residue in the SH2-kinase linker, Leu-255, has been shown to be important in repression of Src activity (103) . In the crystal structure of Src, Leu-255, which is located two residues after the PXXX motif in the SH2-linker, is inserted into a hydrophobic pocket formed by Trp-286 and Tyr-326 in the amino-terminal (104) and Lck (82) have been superimposed. The protein kinaseinvariant lysine in β-strand 3 (β3) and glutamic acid in α-helix C (αC) are shown in ball-and-stick representation. In the phosphorylated (active) Lck structure, the salt bridge between Lys-273 and Glu-288 is shown as a dotted line. In the structure of downregulated Src, the salt bridge is not formed because of the misalignment of helix C. kinase lobe. Hydrophobicity at residue 255 is conserved in other Src family members, as is the hydrophobic pocket, which suggests an important role for this interaction. Indeed, even conservative substitutions of Leu-255 (Leu-255→Ala or Leu-255→Val) completely deregulate the enzyme, rendering it constitutively active (103) .
Autophosphorylation of Tyr-416 in the Src activation loop is required for maximal kinase activity. In the original crystal structures of Src and Hck, the activation loop is largely disordered (94) (95) (96) . Therefore, it appeared that the activation loop played a passive role in repression, and that autophosphorylation merely stabilizes the active conformation of the loop. More recent structures of Src and Hck indicate that the activation loop is indeed involved in stabilization of the repressed form of Src/Hck (104, 105) . In these structures, the segment of the activation loop containing Tyr-416 forms a short 3 10 helix, with Tyr-416 situated in a hydrophobic pocket within the catalytic cleft of the kinase domain. The interactions involving Tyr-416 serve to occlude the substrate-binding site and protect Tyr-416 from autophosphorylation.
Src can be activated by disruption of the intramolecular restraints on the kinase domain that are mediated by the SH2 and SH3 domains. Displacement of the SH2 and SH3 domains from the carboxy-terminal tail and SH2-kinase linker, respectively, can occur through binding of high-affinity ligands. For example, Src can be activated through SH2 domain binding to the autophosphorylated PDGF receptor (43, 106) or through SH3 domain binding to the HIV protein Nef (107) . Dual SH2-SH3 domain binding to sequences within the NRTK Fak potently activates Src (108) . Disruption of the intramolecular restraints in Src is thought to destabilize the nonproductive position of helix C and the inhibitory conformation of the activation loop, which exposes Tyr-416 for autophosphorylation. The culmination of these structural changes is the optimal positioning of kinase residues that are critical for catalysis.
CONCLUSIONS AND PROSPECTS
High-resolution structural studies of RTKs and NRTKs, together with a wealth of biochemical and genetic data, are continuing to reveal the precise molecular mechanisms underlying (a) ligand recognition by RTKs, (b) dimerization and activation of RTKs, (c) regulation of catalytic activity in NRTKs, and (d) specificity in PTK signaling. Future challenges will be determining the structures of additional ligand-RTK complexes and NRTKs, as well as gaining a more detailed understanding of the regulatory mechanisms for PTKs whose structures are known.
In addition to providing a fundamental understanding of this important class of enzymes, structural studies also provide an opportunity for the rational design of inhibitors capable of interfering with PTK catalytic activity. Given the importance of PTKs in signaling pathways that lead to cell proliferation, it is not surprising that numerous RTKs and NRTKs have been implicated in the onset/progression of diseases such as cancer, diabetic retinopathy, atherosclerosis, and psoriasis (109) . Potential targets of PTK inhibitors include the ligand-binding sites on RTKs, the ATP-and peptide substrate-binding sites in the tyrosine kinase domain, and the recruitment sites on PTKs to which downstream signaling proteins bind. Thus far, the ATP-binding site in the tyrosine kinase domain has proven to be the most tractable target, and ATP-competitive inhibitors exhibit a surprising degree of specificity given the general sequence conservation in the ATP-binding pocket of protein kinases. Numerous structures of PTKs in complex with ATP-competitive inhibitors are now available (105, (110) (111) (112) (113) , which reveal the structural basis for this specificity.
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